Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation
Open Access
- 1 February 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (2), 882-889
- https://doi.org/10.1128/aac.01061-09
Abstract
The mechanism by which entecavir resistance (ETVr) substitutions of hepatitis B virus (HBV) can induce breakthrough (BT) during ETV therapy is largely unknown. We conducted a cross-sectional study of 49 lamivudine (LVD)-refractory patients and 59 naïve patients with chronic hepatitis B. BT was observed in 26.8% of the LVD-refractory group during weeks 60 to 144 of ETV therapy. A line probe assay revealed ETVr substitutions only in the LVD-refractory group, i.e., in 4.9% of patients at baseline, increasing to 14.6%, 24.4%, and 44.8% at weeks 48, 96, and 144, respectively. Multivariate logistic regression analysis adjusted for age, gender, HBV DNA levels, and LVD resistance (LVDr) (L180M and M204V, but not M204I) indicated that T184 substitutions and S202G (not S202C) were a significant factor for BT (adjusted odds ratio [OR], 141.12, and 95% confidence interval [CI], 6.94 to 2,870.20; OR, 201.25, and 95% CI, 11.22 to 3608.65, respectively). Modeling of HBV reverse transcriptase (RT) by docking simulation indicated that a combination of LVDr and ETVr (T184L or S202G) was characterized by a change in the direction of the D205 residue and steric conflict in the binding pocket of ETV triphosphate (ETV-TP), by significantly longer minimal distances (2.2 Å and 2.1 Å), and by higher potential energy (−117 and −99.8 Kcal/mol) for ETV-TP compared with the wild type (1.3 Å; −178 Kcal/mol) and LVDr substitutions (1.5 Å; −141 Kcal/mol). Our data suggest that the low binding affinity of ETV-TP for the HBV RT, involving conformational change of the binding pocket of HBV RT by L180M, M204V plus T184L, and S202G, could induce BT.Keywords
This publication has 28 references indexed in Scilit:
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceHepatology, 2008
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Evolution of multi-drug resistant hepatitis B virus during sequential therapyHepatology, 2006
- Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis BGastroenterology, 2006
- Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search EngineJournal of Medicinal Chemistry, 2003
- Extending the accuracy limits of prediction for side-chain conformationsJournal of Molecular Biology, 2001
- The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceJCI Insight, 2001
- Basic Local Alignment Search ToolJournal of Molecular Biology, 1990
- Basic local alignment search toolJournal of Molecular Biology, 1990